

A conceptual image featuring a close-up of two hands shaking in a firm grip. The hands are wearing dark suit sleeves with light-colored striped cuffs. Overlaid on the hands is a stylized world map, with the continents appearing in a light, textured blue and the oceans in a darker blue. The background of the entire image is a solid, vibrant blue, with a diagonal white line separating the handshake image from the bottom-left corner.

# THE COVAX FACILITY

# GLOBAL COLLABORATION

A close-up photograph of two hands shaking in a firm grip, symbolizing collaboration. The hands are positioned over a stylized world map, which is partially visible in the upper right corner of the slide. The background of the slide is a solid blue color.

- The need
  - Accelerate the development and manufacture of COVID-19 vaccines, diagnostics and treatments
  - Guarantee rapid, fair and equitable access to all countries
- Governments, health organizations, scientists, businesses, civil society, and philanthropists.....
  - Joined forces to speed up efforts to end the pandemic

# COVAX FACILITY

- Established April 2020
- COVAX - COVID-19 Vaccine Global Access (COVAX) Facility
  - WHO / PAHO
  - UNICEF
  - World Bank
  - Global Alliance for Vaccines and Immunizations (GAVI) Secretariat
  - Coalition for Epidemic Preparedness Innovations (CEPI)



# COVAX FACILITY CONT'D

- The COVAX Facility pools purchasing power
  - Speak to the manufacturers - USD 8.70-37.00
  - Negotiate best price
    - Estimated price possibly US\$10 - \$20 per dose
    - There may be tiered pricing or one single flat price



# COVAX FACILITY CONT'D

- Diversified portfolio across different technologies, geographies and vaccine characteristics
- Inclusion of candidates are based on:
  - Assessment by COVAX advisory committees
  - Joint tender for procurement and supply agreements by UNICEF / PAHO





# COVAX FACILITY CONT'D

- Candidates are assessed on
  - Efficacy
  - Probability of success
  - Safety and immunogenicity
  - Availability of supply
    - Regional scope & scalability
  - Programmatic feasibility
    - Delivery considerations
    - Timing of doses
  - Pricing



# COVAX FACILITY CONT'D

- The Facility continually monitors the COVID-19 vaccine landscape
- Identifies the most suitable vaccine candidates
  - Based on scientific merit and scalability



# COVAX CONT'D

## Commitment

- Provide at least **2 billion doses** by the end of 2021
- 500 million doses have been secured for Q1 and Q2
- End the acute phase of the pandemic by end of 2021
- Guarantee vaccine access to every participating country





# COVAX OFFER UPTAKE

- All countries were invited to participate
  - 190 (Jan 2021)
- Countries participating in the Facility benefit from the assurance that the Facility can supply them with enough vaccine doses to immunize 20% of their country's population
- Receive vaccines at the negotiated price



# COVAX OFFER UPTAKE CONT'D



## Americas

- PAHO Revolving Fund (RF) are being represented as a unified “bloc” in the Facility
- RF mechanism is recognized as a viable procurement channel
- All vaccines will be PAHO/WHO prequalified
  - Reviewed and sanctioned by the various expert advisory groups

# INDEMNITY

- Countries are required to sign indemnification agreement before vaccines will be issued through the COVAX Facility
- Vaccines may be available approximately 6-8 weeks after




# INDEMNITY CONT'D

- USA
  - Legislative immunity to manufacturers
  - No one can bring a claim against the manufacturer
  - Alternate compensation method in place




# VACCINE LANDSCAPE

As at 22 January







Technology	Attributes			
	Single dose	Already licensed technology	Speed of scale production	Current production scale
Inactivated virus	No	Yes	Medium	Medium/high
Attenuated virus	Yes	Yes	Slow	High
DNA-based	No	No	Fast	Medium
RNA-based	No	No	Fast	Low/medium
Viral vector	Maybe	Yes*	Medium	High
Protein-based	No	Yes	Medium/Fast	High

# VACCINE LANDSCAPE CONT'D

Platform		Candidate vaccines (no. and %)	
PS	Protein subunit	20	31%
VVnr	Viral Vector (non-replicating)	10	16%
DNA	DNA	8	13%
IV	Inactivated Virus	9	14%
RNA	RNA	7	11%
VVr	Viral Vector (replicating)	4	6%
VLP	Virus Like Particle	2	3%
VVr + APC	VVr + Antigen Presenting Cell	2	3%
LAV	Live Attenuated Virus	1	2%
VVnr + APC	VVnr + Antigen Presenting Cell	1	2%
		64	

# AstraZeneca

- Several manufacturers
- Indemnity forms required for each manufacturer
- 50 million doses will be available in Feb & Mar  
Another 100 million doses available for delivery in Q2 2021
- 90 million additional doses from SII in Q1 2021, with another 150 million doses anticipated to become available in Q2 2021




# OTHER VACCINES

Second half of 2021

- Single dose Johnson & Johnson/Janssen vaccine
- Novavax from multiple producers
- Sanofi/GSK
- Sinopharm







# NEW WAVE

- Expedited supply
- Pfizer vaccine now being offered through the COVAX Facility
- Available in February



# JAMAICA



# AGREEMENT

- Government of Jamaica signed a commitment agreement with GAVI Alliance
  - Self financing
- Vaccinate 16% of our population in Phase 1
  - 935,676 doses
- Cost of USD10.55



# NEXT STEPS

- Indemnification
- WHO/PHAO prequalification
- Acceptance of the Price Estimate
  - 6-8 weeks
- Arrears to the RF honored



# VACCINE ARRIVAL

- 146,400-249,600 doses in February/March
- 65-75% in Q2





*Thank You*

